

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: WARSHAWSKY=3

In re Application of:)	Art Unit:
Abraham WARSHAWSKY et al.)	
)	Examiner:
)	
I.A. No.: PCT/IL00/00332)	Washington, D.C.
)	
Filed: June 7, 2000)	December 7, 2001
)	
For: PHARMACEUTICAL COMPOSITIONS...))	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] B. before the mailing date of a first office action on the merits.

[] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

[] i. Counsel certifies that, upon information and belief, each item of information listed herein was either

[] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

[] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

[] ii. A check (check no. _____) for the fee set forth in §1.17(p), presently believed to be \$180, is enclosed.

[] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$180.

[] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) petitions under 37 CFR §1.97(d) for consideration of this IDS. A check (check no. _____) for/ Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(i), presently believed to be \$130 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was either

[] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

[] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any

individual designated in §1.56(c) more than three months prior to the filing of this IDS.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

[] A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449 from the files of the prior application(s) or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance with §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

[X] 3. Document AB is not in the English language. In accordance with §1.98(c), Applicant(s) states:

[] An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.

[X] A concise explanation of the relevance of documents AA-AN is found in the attached International search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] A concise explanation of the relevance of document(s) _____ is set forth as follows:

JC13 Rec'd PCT/PTO 07 DEC 2001

☐ A concise explanation of the relevance of document(s) _____ can be found on page(s) ____ of the specification.

☐ A concise explanation of document(s) _____ can be found on the attached sheet.

☒ 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).


☐ 5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Roger L. Browdy
Reg. No. 25,618

624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
F:\,B\Bena\Warshawaky3\PTO\ids.fee.doc

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

I.A. Number	PCT/IL00/00332
Filing Date	June 7, 2000
First Named Inventor	Abraham WARSHAWSKY et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	WARSHAWSKY=3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,652,519	A1	WARSHAWSKY et al.	Mar. 24, 1987	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Office ³	Foreign Patent Number	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AB	JP	63-238060			Oct. 4, 1988		
	AC	EP	0 329 481	A2	FRITZBERG et al.	Aug. 23, 1989		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AD	KAHANA N et al.: "A CONCEPTUAL APPROACH TO THE SYNTHESIS OF BIFUNCTIONAL EDTA ANALOGSEDTA-EXTENDED POLYAMIDES", Journal of Organic Chemistry, US, American Chemical Society, Easton, vol. 59, no. 17, 26 August 1994 (1994-08-26), pgs. 4832-4837, XP000576114	
	AE	WARSHAWSKY A.: "BIFUNCTIONAL CHELATING AGENTS PART 3", J. Chem. Soc. Perkin Trans. I, vol. 10, 1989, pgs 1781-6 XP002155815	
	AF	HALL E D et al. "NEUROPROTECTIVE EFFICACY OF MICROVASCULARLY-LOCALIZED VERSUS BRAIN-PENETRATING ANTIOXIDANTS.", Acta Neurochirurgica. Supplementum, (1996) 66 107-13 Ref: 23, XP000972206	
	AG	WESEMANN, W. (1) et al. "EFFECT OF LAZAROID U-74389G ON IRON-INDUCED REDUCTION OF STRIATAL DOPAMINE METABOLISM", Journal Of Neural transmission Supplement, (1995) vol. 46, No. 0, pgs. 175-182	
	AH	BEN-SHACHAR D et al. "IRON MELANIN INTERACTION AND LIPID PEROXIDATION IMPLICATIONS FOR PARKINSON'S DISEASE" J Neurochem, (1991) 57 (5), 1609-1614, XP000972207	
	AI	WARSHAWSKY A et al. "CYTOTOXICITY EFFECTS OF TRANSITION-METAL CHELATORS OF THE 5-SUBSTITUTED 2-HYDROXYACETOPHENONES AND THEIR OXIMES", European Journal Of Medicinal Chemistry, vol. 30, no. 7-8, 1995, pgs. 553-560, XP002163945	
	AJ	KIRIENKO, G. K. et al. "DERIVATIVES OF 8-HYDROXYQUINOLINE AS POSSIBLE ANTHELMINTICS, NEMATOCIDES, AND FUNGICIDES" retrieved from STN, Database accession no. 70:106350 HCA, XP002163950	
	AK	WARNER VD et al. "QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS FOR 5-SUBSTITUTED 8-HYDROXYQUINOLINES AS INHIBITORS OF DENTAL PLAQUE", Journal Of Medicinal Chemistry, (1976 Jan) 19 (1) pgs.92-6. XP002163946	
	AL	WARNER V D et al. "SYNTHESIS AND IN VITRO EVALUATION OF 8-HYDROXYQUINOLINE ANALOGS AS INHIBITORS OF DENTAL PLAQUE" Journal Of Medicinal Chemistry, (1976 Jan) 19 (1) pgs. 167-9	
	AM	BURCKHALTER et al. "AMINO AND CHLOROMETHYLATION OF 8- QUINOLINOL-MECHANISM OF PREPONDERANT ORTHO SUBSTITUTION IN PHENOLS UNDER MANNICH CONDITIONS", Journal Of Organic Chemistry, vol. 26, Oct. 1961 (1961-10), pgs. 4078-4083, XP002163948 pg. 4078-4083	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	AN	MATSUMURA et al. "CONDENSATION OF CHLORAL HYDRATE WITH 8-QUINOLINOL", Journal Of The Americal Chemical Society, 1955, pgs. 6671-6674, XP002163949	
	AO		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.